---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-035521"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2024-11-15T23:59:59+00:00"
generated_at: "2026-05-29T23:50:10.167862+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NRx Q3 net operating loss down 74% to $1.6M; on track for NDA filings by year-end

## Summary
- Net operating loss $1.6M in Q3 2024 vs $6.1M in Q3 2023; nine-month net loss $16.1M vs $25.8M.
- Cash $1.6M at Sep 30; closed $5.4M second tranche from Anson Funds post-quarter; $10.8M total convertible debt.
- Expects to file NDAs for NRX-100 (IV ketamine) and NRX-101 (bipolar depression) by end of 2024, with 2025 PDUFA dates.
- HOPE Therapeutics signed two non-binding LOIs to acquire Interventional Psychiatry Clinics; first revenue forecast by year-end 2024.
- Retired Streeterville debt at substantial discount; litigation settled.

## SEC filing metadata
- accession: 0001437749-24-035521
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2024-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000143774924035521/0001437749-24-035521-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000143774924035521/nrxp20241115_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-035521
- JSON: https://secwatch.observer/filing/0001437749-24-035521.json
- Plain text: https://secwatch.observer/filing/0001437749-24-035521.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.